BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 34774537)

  • 1. MicroRNA Regulation of T-Cell Exhaustion in Cutaneous T Cell Lymphoma.
    Han Z; Estephan RJ; Wu X; Su C; Yuan YC; Qin H; Kil SH; Morales C; Schmolze D; Sanchez JF; Tian L; Yu J; Kortylewski M; Rosen ST; Querfeld C
    J Invest Dermatol; 2022 Mar; 142(3 Pt A):603-612.e7. PubMed ID: 34774537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MicroRNA expression in early mycosis fungoides is distinctly different from atopic dermatitis and advanced cutaneous T-cell lymphoma.
    Ralfkiaer U; Lindahl LM; Litman T; Gjerdrum LM; Ahler CB; Gniadecki R; Marstrand T; Fredholm S; Iversen L; Wasik MA; Bonefeld CM; Geisler C; Krejsgaard T; Glue C; Røpke MA; Woetmann A; Skov L; Grønbæk K; Odum N
    Anticancer Res; 2014 Dec; 34(12):7207-17. PubMed ID: 25503151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histone deacetylase inhibitors inhibit metastasis by restoring a tumor suppressive microRNA-150 in advanced cutaneous T-cell lymphoma.
    Abe F; Kitadate A; Ikeda S; Yamashita J; Nakanishi H; Takahashi N; Asaka C; Teshima K; Miyagaki T; Sugaya M; Tagawa H
    Oncotarget; 2017 Jan; 8(5):7572-7585. PubMed ID: 27935859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of STAT4 expression in cutaneous T-cell lymphoma (CTCL) patients and patient-derived cell lines.
    Litvinov IV; Cordeiro B; Fredholm S; Ødum N; Zargham H; Huang Y; Zhou Y; Pehr K; Kupper TS; Woetmann A; Sasseville D
    Cell Cycle; 2014; 13(18):2975-82. PubMed ID: 25486484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical Targeting of MicroRNA-214 in Cutaneous T-Cell Lymphoma.
    Kohnken R; McNeil B; Wen J; McConnell K; Grinshpun L; Keiter A; Chen L; William B; Porcu P; Mishra A
    J Invest Dermatol; 2019 Sep; 139(9):1966-1974.e3. PubMed ID: 30876800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diminished microRNA-29b level is associated with BRD4-mediated activation of oncogenes in cutaneous T-cell lymphoma.
    Kohnken R; Wen J; Mundy-Bosse B; McConnell K; Keiter A; Grinshpun L; Hartlage A; Yano M; McNeil B; Chakravarti N; William B; Bradner JE; Caligiuri MA; Porcu P; Mishra A
    Blood; 2018 Feb; 131(7):771-781. PubMed ID: 29180399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigenetic Silencing of Tumor Suppressor miR-124 Directly Supports STAT3 Activation in Cutaneous T-Cell Lymphoma.
    García-Colmenero L; González J; Sandoval J; Guillén Y; Diaz-Lagares A; Andrades E; Iglesias A; Nonell L; Pujol RM; Bigas A; Espinosa L; Gallardo F
    Cells; 2020 Dec; 9(12):. PubMed ID: 33333886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Downregulation of miR-26 promotes invasion and metastasis via targeting interleukin-22 in cutaneous T-cell lymphoma.
    Matsuda Y; Ikeda S; Abe F; Takahashi Y; Kitadate A; Takahashi N; Wakui H; Tagawa H
    Cancer Sci; 2022 Apr; 113(4):1208-1219. PubMed ID: 35133054
    [TBL] [Abstract][Full Text] [Related]  

  • 9. miR-337 suppresses cutaneous T-cell lymphoma via the STAT3 pathway.
    Xia L; Wu L; Xia H; Bao J; Li Q; Chen X; Xia R
    Cell Cycle; 2019 Jul; 18(14):1635-1645. PubMed ID: 31213131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Jak3, STAT3, and STAT5 inhibit expression of miR-22, a novel tumor suppressor microRNA, in cutaneous T-Cell lymphoma.
    Sibbesen NA; Kopp KL; Litvinov IV; Jønson L; Willerslev-Olsen A; Fredholm S; Petersen DL; Nastasi C; Krejsgaard T; Lindahl LM; Gniadecki R; Mongan NP; Sasseville D; Wasik MA; Iversen L; Bonefeld CM; Geisler C; Woetmann A; Odum N
    Oncotarget; 2015 Aug; 6(24):20555-69. PubMed ID: 26244872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. miR-122 regulates p53/Akt signalling and the chemotherapy-induced apoptosis in cutaneous T-cell lymphoma.
    Manfè V; Biskup E; Rosbjerg A; Kamstrup M; Skov AG; Lerche CM; Lauenborg BT; Odum N; Gniadecki R
    PLoS One; 2012; 7(1):e29541. PubMed ID: 22235305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary T Cells from Cutaneous T-cell Lymphoma Skin Explants Display an Exhausted Immune Checkpoint Profile.
    Querfeld C; Leung S; Myskowski PL; Curran SA; Goldman DA; Heller G; Wu X; Kil SH; Sharma S; Finn KJ; Horwitz S; Moskowitz A; Mehrara B; Rosen ST; Halpern AC; Young JW
    Cancer Immunol Res; 2018 Aug; 6(8):900-909. PubMed ID: 29895574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. STAT5-mediated expression of oncogenic miR-155 in cutaneous T-cell lymphoma.
    Kopp KL; Ralfkiaer U; Gjerdrum LM; Helvad R; Pedersen IH; Litman T; Jønson L; Hagedorn PH; Krejsgaard T; Gniadecki R; Bonefeld CM; Skov L; Geisler C; Wasik MA; Ralfkiaer E; Ødum N; Woetmann A
    Cell Cycle; 2013 Jun; 12(12):1939-47. PubMed ID: 23676217
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PAK1 overexpression promotes cell proliferation in cutaneous T cell lymphoma via suppression of PUMA and p21.
    Wang Y; Gu X; Li W; Zhang Q; Zhang C
    J Dermatol Sci; 2018 Apr; 90(1):60-67. PubMed ID: 29307600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MicroRNA-16 mediates the regulation of a senescence-apoptosis switch in cutaneous T-cell and other non-Hodgkin lymphomas.
    Kitadate A; Ikeda S; Teshima K; Ito M; Toyota I; Hasunuma N; Takahashi N; Miyagaki T; Sugaya M; Tagawa H
    Oncogene; 2016 Jul; 35(28):3692-704. PubMed ID: 26640145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of the MIR155 host gene in physiological and pathological processes.
    Elton TS; Selemon H; Elton SM; Parinandi NL
    Gene; 2013 Dec; 532(1):1-12. PubMed ID: 23246696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aberrant CD137 ligand expression induced by GATA6 overexpression promotes tumor progression in cutaneous T-cell lymphoma.
    Kamijo H; Miyagaki T; Shishido-Takahashi N; Nakajima R; Oka T; Suga H; Sugaya M; Sato S
    Blood; 2018 Nov; 132(18):1922-1935. PubMed ID: 30194255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. STAT5 induces miR-21 expression in cutaneous T cell lymphoma.
    Lindahl LM; Fredholm S; Joseph C; Nielsen BS; Jønson L; Willerslev-Olsen A; Gluud M; Blümel E; Petersen DL; Sibbesen N; Hu T; Nastasi C; Krejsgaard T; Jæhger D; Persson JL; Mongan N; Wasik MA; Litvinov IV; Sasseville D; Koralov SB; Bonefeld CM; Geisler C; Woetmann A; Ralfkiaer E; Iversen L; Odum N
    Oncotarget; 2016 Jul; 7(29):45730-45744. PubMed ID: 27329723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular profiling of TOX-deficient neoplastic cells in cutaneous T cell lymphoma.
    Xu J; Huang H; Wang S; Chen Y; Yin X; Zhang X; Zhang Y
    Arch Dermatol Res; 2020 Sep; 312(7):513-525. PubMed ID: 31676945
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single-Cell Lymphocyte Heterogeneity in Advanced Cutaneous T-cell Lymphoma Skin Tumors.
    Gaydosik AM; Tabib T; Geskin LJ; Bayan CA; Conway JF; Lafyatis R; Fuschiotti P
    Clin Cancer Res; 2019 Jul; 25(14):4443-4454. PubMed ID: 31010835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.